STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism (STRATEGY-PE)
Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study
研究概览
地位
详细说明
Background: Acute pulmonary embolism (PE) is a severe manifestation of venous thromboembolism (VTE). Intermediate-high risk PE accounts for 20-30% of all PE cases with significant mortality driven by right ventricular (RV) dysfunction. Current guidelines recommend anticoagulation for all, with thrombolysis or mechanical thrombectomy as rescue or alternative therapies. However, there is significant heterogeneity in real-world treatment selection and a lack of head-to-head comparative evidence among the three strategies in complex real-world populations.
Objective: To compare the 30-day and 90-day all-cause mortality and 48-hour RV/LV ratio improvement rate among three treatment strategies (Anticoagulation, Thrombolysis, Mechanical Thrombectomy) in patients with intermediate-high risk acute PE.
Design: This is a prospective, multicenter, non-randomized, pragmatic cohort study. Treatment allocation is based on routine clinical decision-making (natural allocation) without investigator intervention. Advanced statistical methods (Propensity Score Matching/Weighting, Instrumental Variable analysis) will be used to control for confounding factors.
Participants: 1,300 patients with confirmed acute intermediate-high risk PE (RV/LV ratio ≥0.9 and elevated cardiac biomarkers, hemodynamically stable). There are no age limits to reflect real-world diversity.
Interventions/Exposures:
- Anticoagulation (AC): Standard anticoagulant therapy (LMWH, DOAC, UFH, or Warfarin).
- Thrombolysis (TL): Systemic thrombolysis or Catheter-Directed Thrombolysis (CDT) using agents like Urokinase, Alteplase, etc.
- Mechanical Thrombectomy (MT): Mechanical removal of thrombus using FDA/NMPA approved devices (e.g., Indigo, FlowTriever, Acoscream), with or without adjunctive anticoagulation/thrombolysis.
Outcomes:
- Primary: 30-day and 90-day all-cause mortality; 48-hour RV/LV ratio improvement rate (≥15% reduction).
- Secondary: Clinical deterioration, major bleeding (ISTH/GUSTO/BARC), functional status (6MWT, NYHA, PVFS), quality of life (PEmb-QoL, EQ-5D-5L), PE recurrence, and healthcare resource utilization.
Follow-up: Patients will be followed at 48 hours, 7 days, 30 days, and 90 days.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:he xu Dr, doctor
- 电话号码:+86 153 6611 0045
- 邮箱:kilogram@163.com
学习地点
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210006
- Nanjing First Hospital
-
接触:
- Interventional Vascular Department Director, doctor
- 电话号码:+86-25-52271000
- 邮箱:kilogram@163.com
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Age unlimited (reflecting real-world population).
- Symptom duration of acute PE ≤ 14 days.
- Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.
- Defined as Intermediate-High Risk PE meeting all of the following:
- RV/LV ratio ≥ 0.9 (by CT or Echocardiography).
- Elevated cardiac biomarkers (Troponin > 99th percentile or BNP > 100 pg/mL).
- Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).
- Able to provide informed consent and complete follow-up.
Exclusion Criteria:
- Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.
- Unable to obtain baseline or follow-up CTPA imaging.
- (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Anticoagulation Cohort
Patients receiving standard anticoagulation therapy alone without thrombolysis or mechanical thrombectomy.
|
Low Molecular Weight Heparin (LMWH), Direct Oral Anticoagulants (DOAC), Unfractionated Heparin (UFH), or Warfarin according to guideline-standard regimens.
其他名称:
|
|
Thrombolysis Cohort
Patients receiving systemic thrombolysis or catheter-directed thrombolysis.
|
Any FDA/NMPA approved mechanical thrombectomy device (e.g., Indigo, FlowTriever, Acoscream) used for clot removal.
其他名称:
|
|
Mechanical Thrombectomy Cohort
Patients undergoing mechanical thrombectomy procedures using percutaneous devices.
|
Urokinase, Pro-urokinase, Alteplase, or Tenecteplase administered systemically or via catheter.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
All-Cause Mortality at 30 Days
大体时间:30 days
|
The percentage of participants who die from any cause within 30 days of enrollment.
|
30 days
|
|
All-Cause Mortality at 90 Days
大体时间:90 days
|
The percentage of participants who die from any cause within 90 days of enrollment.
|
90 days
|
|
Right Ventricular to Left Ventricular (RV/LV) Ratio Improvement Rate at 48 Hours
大体时间:48 hours ± 6 hours
|
The proportion of participants with a reduction in RV/LV ratio ≥15% from baseline measured by CTPA or Echocardiography.
|
48 hours ± 6 hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major Bleeding Events
大体时间:48 hours, 7 days, 30 days, 90 days
|
Incidence of major bleeding defined by ISTH, GUSTO, or BARC criteria (including intracranial hemorrhage).
|
48 hours, 7 days, 30 days, 90 days
|
|
Clinical Deterioration
大体时间:48 hours, 7 days
|
Composite of hemodynamic instability, need for rescue therapy (escalation to thrombolysis/MT/ECMO), intubation, or PE-related death.
|
48 hours, 7 days
|
|
6-Minute Walk Test (6MWT) Distance
大体时间:30 days, 90 days
|
Change in walking distance from baseline (estimated) to follow-up.
Minimal Clinically Important Difference (MCID) ≥30 meters.
|
30 days, 90 days
|
|
Post-VTE Functional Status (PVFS) Score
大体时间:30 days, 90 days
|
Assessment of functional limitation due to VTE (Scale 0-5).
|
30 days, 90 days
|
|
Quality of Life (PEmb-QoL)
大体时间:90 days
|
The questionnaire consists of 9 questions containing 40 items, which are organized into 6 domains: Frequency of Complaints (FC): Assesses the frequency of respiratory and general symptoms (e.g., dyspnea, chest pain). Daily Activity Limitations (AL): Measures limitations in performing activities of daily living (ADL). Work-related Problems (WP): Evaluates difficulties in performing work or school duties. Social Limitations (SL): Assesses restrictions on social activities. Intensity of Complaints (IC): Measures the severity of pain and breathlessness. Emotional Complaints (EC): Captures anxiety, frustration, and fear related to the disease. |
90 days
|
|
Symptomatic PE Recurrence
大体时间:90 days
|
Confirmed recurrent PE via CTPA or V/Q scan.
|
90 days
|
|
ICU Length of Stay
大体时间:From ICU admission to ICU discharge, assessed up to 30 days
|
Duration of intensive care unit stay during the index hospitalization
|
From ICU admission to ICU discharge, assessed up to 30 days
|
|
Total Hospital Length of Stay
大体时间:From hospital admission to hospital discharge, assessed up to 90 days
|
Duration of index hospitalization from emergency department admission to hospital discharge
|
From hospital admission to hospital discharge, assessed up to 90 days
|
|
Total Medical Costs
大体时间:Through 90 days
|
Direct medical costs incurred during index hospitalization and within 90 days of enrollment, including medications, procedures, and hospitalization
|
Through 90 days
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Biomarker Improvement (Troponin, BNP, D-Dimer)
大体时间:48 hours, 7 days
|
Percentage reduction in cardiac biomarkers and D-Dimer levels.
|
48 hours, 7 days
|
|
Daily Step Count
大体时间:Continuous monitoring through 90 days
|
Average daily step count measured by smart band (e.g., Xiaomi/Huawei/Apple Watch) during the 90-day follow-up period.
Assessed as a continuous variable (steps/day) and correlated with 6-Minute Walk Test distance and Post-VTE Functional Status score.
|
Continuous monitoring through 90 days
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 血管疾病
- 心血管疾病
- 呼吸道疾病
- 肺部疾病
- 栓塞和血栓形成
- 栓塞
- 血栓栓塞
- 肺栓塞
- 静脉血栓栓塞症
- 药理作用的分子机制
- 纤维蛋白调节剂
- 氨基酸,肽和蛋白质
- 蛋白质
- 硫化合物
- 有机化学品
- 吡啶
- 杂环化合物,1形
- 杂环化合物
- 苯甲酰唑
- 杂环化合物,2环
- 杂环化合物,融合环
- 比尔
- 药理作用
- 化学作用和用途
- 治疗用途
- 碳水化合物
- 水解酶
- 酶
- 酶和辅酶
- 血蛋白
- 肝素,低分子量
- 糖胺聚糖
- 多糖
- 吗啡
- 奥沙嗪
- 硫苯
- 香豆素
- 苯佐皮人
- 内肽酶
- 肽水解酶
- 丝氨酸内肽酶
- 丝氨酸蛋白酶
- 纤溶酶原激活剂
- 血液凝血因子
- 心血管剂
- 4-羟基木菊
- 组织纤溶酶原活化剂
- 血液学剂
- 利伐沙班
- 达比加群酯
- 替奈普酶
- 依诺肝素
- 华法林
- 肝素
- 抗凝剂
- 纤溶剂
- apixaban
- Edoxaban
- Urokinase-Type Plasminogen Activator
其他研究编号
- KY20260205-04
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.